Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

Even if the FDA agrees the half-life in humans will be short based on preclinical data, you are still missing the point.

The primary concern of the FDA in P1 is safety/side effects, regardless of its half-life. Drugs with short half-life can be toxic. From what I've seen in similar trials, the standard protocol seems to be once a week dosing for IV. Most chemotherapy drugs are toxic, so the FDA isn't going to agree to multiple dosing without knowing the drug's side effects and PK/PD data first.

Dose optimizations are what P2 is for, which K is about to start. That's just the way it is.

One enters into google search kevetrin half life to discover , with one click, directly from the CTIX website that K has a half life in mice and rats of .7 to 2.2 hrs and 1 hour in dogs